Diligence memo · auto-generated · as of July 2, 2026
Ambrx Inc
Ambrx Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Ambrx Inc operates in Biotechnology, based in LA JOLLA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ambrx Inc has raised $10M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2009-03-17.
Most recent recorded round closed around 2009-03-17.
Valuation (modeled)modeled
Provath models Ambrx Inc at approximately $362M (range $11M–$2.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.22× the median modeled value of Series A Biotechnology companies in 2007–2009 (35 peers) — value vs value, same stage and era. Within the normal band (122% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 17.3 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 56% of Biotechnology peers (4293 compared).
Modeled value ranks above 79% of those peers.
Closest niche peers: Complete Genomics Inc, BioTrove, Inc., Aliva Biopharmaceuticals, LLC, Molecular Biometrics Inc, Bioimagene Inc.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.